Browsing byAuthorAlvaro, F

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 5 to 8 of 8< previous 
Issue DateTitleAuthor(s)
2021-10-04Long-term health-related quality of life in young childhood cancer survivors and their parents.Fardell, JE; Wakefield, CE; De Abreu Lourenco, R; Signorelli, C; McCarthy, M; McLoone, J; Osborn, M; Gabriel, M; Anazodo, A; Alvaro, F; Lockwood, L; Walwyn, T; Skeen, J; Tillemans, R; Cohn, RJ; ANZCHOG Survivorship Group,
2022-03-01Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia.Mateos, MK; Marshall, GM; Barbaro, PM; Quinn, MCJ; George, C; Mayoh, C; Sutton, R; Revesz, T; Giles, JE; Barbaric, D; Alvaro, F; Mechinaud, F; Catchpoole, D; Lawson, JA; Chenevix-Trench, G; MacGregor, S; Kotecha, RS; Dalla-Pozza, L; Trahair, TN
2022-09-15Prospective longitudinal evaluation of treatment-related toxicity and health-related quality of life during the first year of treatment for pediatric acute lymphoblastic leukemia.Schilstra, CE; McCleary, K; Fardell, JE; Donoghoe, MW; McCormack, E; Kotecha, RS; Lourenco, RDA; Ramachandran, S; Cockcroft, R; Conyers, R; Cross, S; Dalla-Pozza, L; Downie, P; Revesz, T; Osborn, M; Alvaro, F; Wakefield, CE; Marshall, GM; Mateos, MK; Trahair, TN
2020-12Shwachman-Bodian-Diamond syndrome (SBDS) protein is a direct inhibitor of protein phosphatase 2A (PP2A) activity and overexpressed in acute myeloid leukaemia.Dun, MD; Mannan, A; Rigby, CJ; Butler, S; Toop, HD; Beck, D; Connerty, P; Sillar, J; Kahl, RGS; Duchatel, RJ; Germon, Z; Faulkner, S; Chi, M; Skerrett-Byrne, D; Murray, HC; Flanagan, H; Almazi, JG; Hondermarck, H; Nixon, B; De Iuliis, G; Chamberlain, J; Alvaro, F; de Bock, CE; Morris, JC; Enjeti, AK; Verrills, NM